secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2026-07-30T11:03:02+00:00
Accession:  0001628280-26-050775
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q2 Rezdiffra sales $364.3M (+71% YoY); net loss $57.9M
---------------------------------------------------------------

- Rezdiffra net sales $364.3M, up 71% from $212.8M in Q2 2025; over 49,000 patients on therapy as of June 30, 2026.
- Net loss $57.9M ($1.99/share) vs. $42.3M ($1.50/share) a year ago; includes $25M one-time business development expense.
- Cash and marketable securities $838.9M as of June 30, 2026, down from $988.6M at Dec. 31, 2025.
- Three new resmetirom patents issued, including one for F4c (well-compensated cirrhosis) with protection into 2042.
- MGL-2086 (oral GLP-1) Phase 1 SAD trial initiated in June 2026 for Rezdiffra combination program in MASH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/0001628280-26-050775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/mdgl-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-050775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer